ArticleOrphanet journal of rare diseases2023

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.

Aleš Linhart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.